Aarti Drugs Ltd

Aarti Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Drugs Ltd

₹ 470 -1.14%
09 Jun 1:28 p.m.
aartidrugs.com BSE: 524348 NSE : AARTIDRUGS
About

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]

It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

Key Points

Largest producer in World
Aarti Drugs Ltd. (ADL) is the largest producer of Fluoroquinolones group, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole in the world. It is one of the leading producers of Metformin in the world. [1]

Website BSE NSE
  • Market Cap ₹ 4,348 Cr.
  • Current Price ₹ 470
  • High / Low ₹ 512 / 311
  • Stock P/E 28.5
  • Book Value ₹ 120
  • Dividend Yield 0.21 %
  • ROCE 15.1 %
  • ROE 14.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
407 476 515 472 452 506 511 593 641 551 625 626 696
339 359 406 374 374 432 442 503 557 496 555 557 608
Operating Profit 68 116 109 98 78 74 69 91 84 55 70 69 89
OPM % 17% 24% 21% 21% 17% 15% 14% 15% 13% 10% 11% 11% 13%
9 1 0 4 1 2 1 2 1 0 0 1 1
Interest 7 6 7 5 4 4 5 5 6 7 8 9 8
Depreciation 12 12 12 12 12 12 12 12 12 12 12 12 12
Profit before tax 57 99 90 85 63 60 53 75 67 36 50 49 69
Tax % 1% 26% 23% 24% 21% 24% 24% 26% 21% 28% 27% 25% 23%
Net Profit 57 73 70 65 50 46 41 56 53 26 37 37 53
EPS in Rs 6.07 7.84 7.49 6.94 5.39 4.92 4.39 6.03 5.72 2.85 3.95 3.96 5.74
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
659 826 972 1,087 1,076 1,089 1,140 1,454 1,635 1,915 2,251 2,498
579 703 822 915 900 910 955 1,252 1,387 1,511 1,930 2,216
Operating Profit 80 123 150 172 176 179 185 203 248 404 321 282
OPM % 12% 15% 15% 16% 16% 16% 16% 14% 15% 21% 14% 11%
2 -0 1 1 0 4 1 6 9 7 5 2
Interest 25 31 37 42 47 38 36 41 36 26 23 33
Depreciation 24 26 28 31 36 37 38 40 47 48 47 47
Profit before tax 32 66 86 100 93 108 112 128 175 338 256 205
Tax % 30% 31% 28% 22% 29% 30% 35% 32% 22% 24% 24% 25%
Net Profit 22 45 62 78 66 75 73 87 136 258 195 153
EPS in Rs 2.32 4.67 6.38 8.01 6.84 7.91 7.78 9.25 14.56 27.65 21.06 16.50
Dividend Payout % 27% 27% 26% 41% 25% 3% 3% 3% 3% 9% 5% 6%
Compounded Sales Growth
10 Years: 12%
5 Years: 17%
3 Years: 15%
TTM: 11%
Compounded Profit Growth
10 Years: 13%
5 Years: 16%
3 Years: 6%
TTM: -22%
Stock Price CAGR
10 Years: 33%
5 Years: 30%
3 Years: 25%
1 Year: 10%
Return on Equity
10 Years: 22%
5 Years: 22%
3 Years: 22%
Last Year: 15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
12 12 12 24 24 24 24 24 23 93 93 93
Reserves 164 196 239 279 326 363 410 495 598 766 880 1,022
272 296 342 435 465 448 517 471 378 336 519 535
164 216 257 228 240 281 366 384 471 442 543 546
Total Liabilities 613 720 850 967 1,055 1,116 1,316 1,373 1,471 1,637 2,035 2,196
274 291 373 431 463 542 564 586 612 631 649 634
CWIP 3 13 8 13 34 14 28 32 11 16 60 161
Investments 7 5 5 11 11 18 17 19 20 24 28 29
329 411 464 511 547 541 707 736 828 966 1,297 1,372
Total Assets 613 720 850 967 1,055 1,116 1,316 1,373 1,471 1,637 2,035 2,196

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
44 72 95 107 125 174 62 147 196 154 40 162
-48 -58 -105 -102 -87 -96 -71 -59 -29 -69 -125 -131
3 -16 11 -5 -37 -78 9 -87 -168 -85 84 -31
Net Cash Flow -0 -2 2 -1 1 -0 -0 1 -1 -0 -1 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 100 95 104 103 109 93 117 110 104 96 115 117
Inventory Days 80 95 71 77 87 101 132 86 107 125 120 100
Days Payable 77 88 84 75 85 91 125 86 110 94 103 88
Cash Conversion Cycle 103 101 91 105 110 103 124 109 101 127 133 129
Working Capital Days 105 101 90 97 108 103 128 108 95 118 132 130
ROCE % 14% 20% 22% 21% 18% 17% 17% 17% 20% 33% 21% 15%

Shareholding Pattern

Numbers in percentages

6 Recently
Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
60.51 60.21 60.20 60.20 60.14 60.12 59.99 59.83 59.98 59.77 59.66 59.57
1.82 2.19 3.06 2.99 2.57 2.21 2.03 2.07 2.07 1.94 1.90 1.94
5.09 2.15 1.68 1.76 2.00 2.12 2.28 2.69 2.76 3.16 3.90 4.09
32.58 35.45 35.07 35.05 35.29 35.55 35.71 35.41 35.19 35.11 34.53 34.39

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls